Shots:

• Neumora has received a $100M as an equity investment and obtains an exclusive global right to develop and commercialize Amgen programs targeting casein kinase 1 delta and glucocerebrosidase for neurodegenerative diseases
• The collaboration will utilize Neumora's precision neuroscience platform with Amgen's deCODE human genetics capabilities to boost innovative therapies for the treatment of brain disease
• Neumora's precision neuroscience platform focuses on the Data Biopsy Signatures to develop the complex systems for brain diseases & develop therapies for an enriched patient population or Precision Phenotypes

  | Ref: PR Newswire | Image: Biospace